{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T05:21:27Z","timestamp":1787721687488,"version":"build-2784847793"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"\n Objective<\/jats:title>\n In eosinophilic diseases, myocardial involvement critically impacts prognosis. Given the rarity and heterogeneity of eosinophilic myocarditis (EM), diagnosis and risk-adapted treatment remain challenging, and longitudinal data on cardiac function are scarce. Therefore, this study investigated the course of cardiac function and aimed to identify prognostic biomarkers in a real-world EM cohort across inflammatory disorders.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n Clinical, laboratory, and imaging data of all patients with eosinophilic myocarditis treated at Ludwig-Maximilians-University Hospital in Munich between January 2010 and May 2025 were reviewed. Descriptive and inferential statistics were applied to delineate disease courses, treatment regimens, and outcomes.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Of 419 patients screened, 51 had EM (51% female patients, mean age 50\u202f\u00b1\u202f14\u202fyears). Underlying diseases included eosinophilic granulomatosis with polyangiitis (EGPA,\n n<\/jats:italic>\n \u202f=\u202f29), idiopathic hypereosinophilic syndrome (i-HES,\n n<\/jats:italic>\n \u202f=\u202f16), drug-associated\/hypersensitivity myocarditis (\n n<\/jats:italic>\n \u202f=\u202f7; 4 with EGPA\/i-HES), and idiopathic EM (\n n<\/jats:italic>\n \u202f=\u202f3). Mean left-ventricular ejection fraction (LVEF) was impaired at baseline (48\u202f\u00b1\u202f17%) and after a median of 34\u202fmonths [interquartile range 16\u201379] (\n \u0394<\/jats:italic>\n \u202f+\u202f3\u202f\u00b1\u202f12%,\n p<\/jats:italic>\n \u202f=\u202f0.57). Laboratory parameters improved (\n p<\/jats:italic>\n \u202f&lt;\u202f0.001); however, LVEF recovered predominantly in patients with baseline evidence of active inflammation on cardiac magnetic resonance (CMR) or endomyocardial biopsy (EMB) (41\u202f\u00b1\u202f15% to 48\u202f\u00b1\u202f10%;\n p<\/jats:italic>\n \u202f&lt;\u202f0.05). Median left-ventricular end-systolic\/end-diastolic volume indices (LVESVI\/-EDVI) increased over time (50 [28\u201365] to 56 [33\u201384] and 85 [68\u201398] to 97 [79\u2013132] mL\/m\n 2<\/jats:sup>\n , respectively;\n p<\/jats:italic>\n \u202f&lt;\u202f0.05), suggesting cardiac remodeling. Glucocorticoids were broadly applied, whereas steroid-sparing drugs were used less frequently. Five patients died, all had reduced baseline LVEF. Age- and sex-adjusted baseline NT-proBNP (log\n 10<\/jats:sub>\n ), LVEF, and the Sartorelli score, a published composite score (incorporating LV dysfunction, arrhythmias, CMR, and serum troponin), were significantly associated with follow-up LVEF, LVEDVI and LVESVI (rho\/\n r<\/jats:italic>\n \u202f=\u202f\u00b10.44\u20130.72,\n R<\/jats:italic>\n 2<\/jats:sup>\n \u202f=\u202f0.19\u20130.64;\n p<\/jats:italic>\n \u202f&lt;\u202f0.05\u2013&lt;0.0001).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n In this real-world cohort, EM severely impacted multiple domains of cardiac function. Treatment patterns were heterogeneous. Baseline NT-proBNP, LVEF, and the Sartorelli score were associated with long-term LVEF and LV remodeling. Baseline evidence of active myocardial inflammation on CMR and\/or EMB was associated with subsequent LVEF improvement. Together, these findings support the utility of multimodal biomarkers for risk stratification in EM but require external validation before informing routine care. Prospective multicenter studies using standardized diagnostics and treatment regimens are needed to translate these findings into biomarker-guided management of eosinophilic cardiomyopathy.<\/jats:p>\n <\/jats:sec>","DOI":"10.3389\/fmed.2026.1887831","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T04:44:50Z","timestamp":1787719490000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Heart failure and predictors of outcome in eosinophilic myocarditis: a real-world cohort study"],"prefix":"10.3389","volume":"13","author":[{"given":"Fabian T. H.","family":"Ullrich","sequence":"first","affiliation":[{"name":"Division of Rheumatology and Clinical Immunology, Department of Medicine IV, LMU University Hospital, LMU Medizin, LMU Munich","place":["Munich, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"Sch\u00f6nermarck","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine IV, LMU University Hospital, LMU Medizin, LMU Munich","place":["Munich, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Milger","sequence":"additional","affiliation":[{"name":"Clinical Department of Pulmonology, Medical University of Graz","place":["Graz, Austria"]},{"name":"Division of Respiratory Medicine, Department of Internal Medicine, Lung Research Cluster, Medical University of Graz","place":["Graz, Austria"]},{"name":"Department of Medicine V, LMU University Hospital, LMU Medizin, LMU Munich","place":["Munich, Germany"]},{"name":"Comprehensive Pneumology Center, German Center for Lung Research (DZL)","place":["Munich, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Murray","sequence":"additional","affiliation":[{"name":"Division of Rheumatology and Clinical Immunology, Department of Medicine IV, LMU University Hospital, LMU Medizin, LMU Munich","place":["Munich, Germany"]},{"name":"Practice of Rheumatology Soest","place":["Soest, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias B.","family":"Thaler","sequence":"additional","affiliation":[{"name":"Division of Rheumatology and Clinical Immunology, Department of Medicine IV, LMU University Hospital, LMU Medizin, LMU Munich","place":["Munich, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didzis","family":"Gailis","sequence":"additional","affiliation":[{"name":"Division of Rheumatology and Clinical Immunology, Department of Medicine IV, LMU University Hospital, LMU Medizin, LMU Munich","place":["Munich, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Lichtnekert","sequence":"additional","affiliation":[{"name":"Division of Rheumatology and Clinical Immunology, Department of Medicine IV, LMU University Hospital, LMU Medizin, LMU Munich","place":["Munich, Germany"]},{"name":"Division of Nephrology, Department of Medicine IV, LMU University Hospital, LMU Medizin, LMU Munich","place":["Munich, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith E.","family":"Spiro","sequence":"additional","affiliation":[{"name":"Department of Radiology, LMU University Hospital, LMU Medizin, LMU Munich","place":["Munich, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenz","family":"Schimang","sequence":"additional","affiliation":[{"name":"Department of Medicine I, LMU University Hospital, LMU Medizin, LMU Munich","place":["Munich, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alla","family":"Skapenko","sequence":"additional","affiliation":[{"name":"Division of Rheumatology and Clinical Immunology, Department of Medicine IV, LMU University Hospital, LMU Medizin, LMU Munich","place":["Munich, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Grabmaier","sequence":"additional","affiliation":[{"name":"Department of Medicine I, LMU University Hospital, LMU Medizin, LMU Munich","place":["Munich, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrik","family":"Schulze-Koops","sequence":"additional","affiliation":[{"name":"Division of Rheumatology and Clinical Immunology, Department of Medicine IV, LMU University Hospital, LMU Medizin, LMU Munich","place":["Munich, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1016\/j.jacc.2017.09.023","article-title":"Eosinophilic myocarditis: characteristics, treatment, and outcomes","volume":"70","author":"Brambatti","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"4538","DOI":"10.1093\/rheumatology\/keab027","article-title":"Heart disease in eosinophilic granulomatosis with polyangiitis (EGPA) patients: a screening approach proposal","volume":"60","author":"Garcia-Vives","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1093\/jleuko\/qiae051","article-title":"Biologic therapy in rare eosinophil-associated disorders: remaining questions and translational research opportunities","volume":"116","author":"Khoury","year":"2024","journal-title":"J Leukoc Biol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"3952","DOI":"10.1093\/eurheartj\/ehaf192","article-title":"2025 ESC guidelines for the management of myocarditis and pericarditis","volume":"46","author":"Schulz-Menger","year":"2025","journal-title":"Eur Heart J"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.21037\/cdt-24-347","article-title":"The Cleveland Clinic experience of eosinophilic myocarditis in the setting of hypereosinophilic syndrome: demographics, cardiac imaging, and outcomes","volume":"14","author":"Reeder","year":"2024","journal-title":"Cardiovasc Diagn Ther"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1093\/rheumatology\/keab514","article-title":"Revisiting characteristics, treatment and outcome of cardiomyopathy in eosinophilic granulomatosis with polyangiitis (formerly Churg-Strauss)","volume":"61","author":"Sartorelli","year":"2022","journal-title":"Rheumatology"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1001\/jama.2023.3371","article-title":"Diagnosis and treatment of acute myocarditis: a review","volume":"329","author":"Ammirati","year":"2023","journal-title":"JAMA"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00393-024-01597-6","article-title":"Diagnosis and treatment of ANCA-associated vasculitis: S3 guideline of the German Society for Rheumatology and Clinical Immunology e. V. (DGRh) and German Society for Internal Medicine e. V. (DGIM), German Society for Nephrology e. V. (DGfN), German society for ENT medicine and head and neck surgery e. V. (DGHNO-KHC), German Ophthalmological Society e. V. (DOG), German Society for Neurology e. V. (DGN), German Society for Pneumology and Respiratory Medicine e. V. (DGP), German Society for Pathology e. V. (DGP), German radiological society, Society for Medical Radiology e. V. (DRG), Federal Association of German Pathologists, Federal Kidney Association e. V., German rheumatism league Federal Association e. V","volume":"84","author":"Holle","year":"2025","journal-title":"Z Rheumatol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1093\/eurheartj\/ehx321","article-title":"Diagnosis and management of myocardial involvement in systemic immune-mediated diseases: a position statement of the European Society of Cardiology Working Group on myocardial and pericardial disease","volume":"38","author":"Caforio","year":"2017","journal-title":"Eur Heart J"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1136\/annrheumdis-2012-201531","article-title":"A vasculitis Centre based management strategy leads to improved outcome in eosinophilic granulomatosis and polyangiitis (Churg-Strauss, EGPA): monocentric experiences in 150 patients","volume":"72","author":"Moosig","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1136\/heartjnl-2020-317202","article-title":"Hypereosinophilic syndrome: considerations for the cardiologist","volume":"108","author":"Bondue","year":"2022","journal-title":"Heart"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"i92","DOI":"10.1093\/rheumatology\/keae608","article-title":"Highlights from the plenary session: eosinophilic granulomatosis with polyangiitis and hypereosinophilic syndrome","volume":"64","author":"Holle","year":"2025","journal-title":"Rheumatology"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1056\/NEJMoa2311155","article-title":"Benralizumab versus mepolizumab for eosinophilic granulomatosis with polyangiitis","volume":"390","author":"Wechsler","year":"2024","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","article-title":"Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis","volume":"376","author":"Wechsler","year":"2017","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/MD.0b013e318205a4c6","article-title":"The five-factor score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort","volume":"90","author":"Guillevin","year":"2011","journal-title":"Medicine (Baltimore)"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1002\/ajh.27287","article-title":"World Health Organization and international consensus classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management","volume":"99","author":"Shomali","year":"2024","journal-title":"Am J Hematol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.jacc.2019.04.063","article-title":"Fulminant versus acute nonfulminant myocarditis in patients with left ventricular systolic dysfunction","volume":"74","author":"Ammirati","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1093\/eurheartj\/eht210","article-title":"Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on myocardial and pericardial diseases","volume":"34","author":"Caforio","year":"2013","journal-title":"Eur Heart J"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s00392-025-02660-1","article-title":"Head-to-head comparison of cardiac magnetic resonance imaging and transthoracic echocardiography in the general population (MATCH)","author":"Wenzel","year":"2025","journal-title":"Clin Res Cardiol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1161\/CIRCHEARTFAILURE.114.001130","article-title":"Management of a patient with eosinophilic myocarditis and normal peripheral eosinophil count: case report and literature review","volume":"7","author":"Fozing","year":"2014","journal-title":"Circ Heart Fail"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.3346\/jkms.2011.26.11.1522","article-title":"Early non-invasive diagnosis and treatment of acute eosinophilic myopericarditis by cardiac magnetic resonance","volume":"26","author":"Kim","year":"2011","journal-title":"J Korean Med Sci"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1136\/ard.2008.088096","article-title":"EULAR recommendations for the management of primary small and medium vessel vasculitis","volume":"68","author":"Mukhtyar","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1136\/annrheumdis-2016-209133","article-title":"EULAR\/ERA-EDTA recommendations for the management of ANCA-associated vasculitis","volume":"75","author":"Yates","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1136\/ard-2022-223764","article-title":"EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update","volume":"83","author":"Hellmich","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1093\/eurheartj\/ehn309","article-title":"ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the heart failure association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM)","volume":"10","author":"Dickstein","year":"2008","journal-title":"Eur J Heart Fail"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1093\/eurheartj\/ehs104","article-title":"ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the heart failure association (HFA) of the ESC","volume":"33","author":"McMurray","year":"2012","journal-title":"Eur Heart J"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)developed with the special contribution of the heart failure association (HFA) of the ESC","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur Heart J"},{"key":"ref30","first-page":"764","article-title":"Hypersensitivity myocarditis","volume-title":"Arch Pathol Lab Med","author":"Burke","year":"1991"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.2169\/internalmedicine.0330-17","article-title":"Dilated cardiomyopathy with eosinophilic granulomatosis with polyangiitis in which active myocardial inflammation was only detected by endomyocardial biopsy","volume":"57","author":"Nakayama","year":"2018","journal-title":"Intern Med"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1136\/heartjnl-2023-323225","article-title":"Eosinophilic myocarditis: systematic review","volume":"110","author":"Techasatian","year":"2024","journal-title":"Heart"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1161\/CIRCULATIONAHA.125.074797","article-title":"Natural history of patients with histologically proven acute eosinophilic myocarditis","volume":"153","author":"Ammirati","year":"2026","journal-title":"Circulation"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"622","DOI":"10.3390\/biomedicines9060622","article-title":"Coronary vasculitis","volume":"9","author":"Gori","year":"2021","journal-title":"Biomedicine"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1007\/s00392-025-02728-y","article-title":"Cardiac disease in patients with vasculitis","volume":"114","author":"Binzenh\u00f6fer","year":"2025","journal-title":"Clin Res Cardiol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12968-020-00683-3","article-title":"Reference ranges (\"normal values\") for cardiovascular magnetic resonance (CMR) in adults and children: 2020 update","volume":"22","author":"Kawel-Boehm","year":"2020","journal-title":"J Cardiovasc Magn Reson"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"3106012","DOI":"10.1155\/2020\/3106012","article-title":"Left ventricular end-systolic volume is a reliable predictor of new-onset heart failure with preserved left ventricular ejection fraction","volume":"2020","author":"Kato","year":"2020","journal-title":"Cardiol Res Pract"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1007\/s00330-018-5875-3","article-title":"Prognosis-based definition of left ventricular remodeling after ST-elevation myocardial infarction","volume":"29","author":"Reindl","year":"2019","journal-title":"Eur Radiol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.echo.2008.11.005","article-title":"Prognostic value of left ventricular end-systolic volume index as a predictor of heart failure hospitalization in stable coronary artery disease: data from the heart and soul study","volume":"22","author":"McManus","year":"2009","journal-title":"J Am Soc Echocardiogr"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.jacc.2020.01.036","article-title":"Ventricular arrhythmias in myocarditis: characterization and relationships with myocardial inflammation","volume":"75","author":"Peretto","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"6366","DOI":"10.1038\/s41598-018-24875-1","article-title":"Association between atrial fibrillation, atrial enlargement, and left ventricular geometric remodeling","volume":"8","author":"Seko","year":"2018","journal-title":"Sci Rep"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1084\/jem.20161702","article-title":"Eosinophil-derived IL-4 drives progression of myocarditis to inflammatory dilated cardiomyopathy","volume":"214","author":"Diny","year":"2017","journal-title":"J Exp Med"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/j.jcmg.2024.05.008","article-title":"Detection of cardiac involvement in eosinophilic granulomatosis with polyangiitis (EGPA) with multiparametric cardiovascular magnetic resonance (CMR)","volume":"17","author":"Hua","year":"2024","journal-title":"JACC Cardiovasc Imaging"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"qyaf010","DOI":"10.1093\/ehjimp\/qyaf010","article-title":"Barriers to cardiovascular magnetic resonance imaging scan performance and reporting by cardiologists: a systematic literature review","volume":"3","author":"Betemariam","year":"2025","journal-title":"Eur Heart J Imaging Methods Pract"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"251","DOI":"10.4103\/jcecho.jcecho_125_20","article-title":"Eosinophilic myocarditis: is endomyocardial biopsy essential for diagnosis in the era of advanced cardiac imaging?","volume":"31","author":"Taskesen","year":"2021","journal-title":"J Cardiovasc Echogr"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.ijcard.2021.02.016","article-title":"Treatment prescription, adherence, and persistence after the first hospitalization for heart failure: a population-based retrospective study on 100785 patients","volume":"330","author":"Scalvini","year":"2021","journal-title":"Int J Cardiol"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1136\/annrheumdis-2012-202603","article-title":"Inequities in access to biologic and synthetic DMARDs across 46 European countries","volume":"73","author":"Putrik","year":"2014","journal-title":"Ann Rheum Dis"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1887831\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T04:44:57Z","timestamp":1787719497000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1887831\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,26]]},"references-count":47,"alternative-id":["10.3389\/fmed.2026.1887831"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1887831","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,26]]},"article-number":"1887831"}}